“硫酸软骨素”和“塞来昔布”治疗成人大骨节病患者的成本效果分析

Cost-effectiveness analysis on Chondroitin sulfate and Celecoxib for adults with Kaschin-Beck disease

目的对"硫酸软骨素"和"塞来昔布"治疗成人大骨节病患者进行成本效果分析,为筛选价格低廉、效果好和副作用小的治疗药物提供依据。方法采用流行病学实验研究的方法,选择阿坝州大骨节病流行区中的成人大骨节病患者200例,随机分为2组,分别服用"硫酸软骨素"和"塞来昔布",长期随访记录WOMAC指数评分和服药情况,计算并比较两组的成本效果。结果当以WOMAC指数改变幅度作为效果指标时,硫酸软骨素组和塞来昔布组的成本效果比C/E1分别为87.07元vs 154.67元,以硫酸软骨素组为基准,塞来昔布组的增量成本效果比△C/△E1为200.11元;当以有效率作为效果指标时,两组的C/E2分别为3 085元vs 3 078元,△C/△E2为3 077元。结论总体上可以认为服用硫酸软骨素较服用塞来昔布方案为优。但这也不是绝对的,如果资源充分,也可考虑选择服用塞来昔布。

Objective To compare the cost - effectiveness between Chondroitin sulfate（CS） and Celicoxib, so as to provide scientific evidences for screening drugs for low prices, effective treatment and small side effects. Methods Total 200 cases included from KBD endemic areas in Aba state were randomly divided into 2 groups, which were respectively taking CS and Celicoxib. Long - term followed up the WOMAC index scores and the situation about patients medication, calculated and compared the cost effectivenss. Results By index change as effect indicator, the cost utility ratios between CS group and Celecoxib group were respectively 87.07 yuan vs 154.67 yuan, the incremental cost effectiveness ratios △C/△ E1 of Celecoxib group was 200.11 yuan to CS group; by effective rate as effect indicator, the cost utility ratios were respectively 3 085 yuan vs 3 078 yuan, the in- cremental cost effectiveness ratios △C/△ E2 was 3 077 yuan. Conclusions From the results of the cost effectiveness ratio, in general, to achieve the same effect CS is much cheaper than Celecoxib. But this is not absolute, if the resources are sufficient, Celecoxib could also be considered.